AstraZeneca PLC (FRA:ZEG)

AstraZeneca Statistics

Total Valuation

AstraZeneca has a market cap or net worth of EUR 258.06 billion. The enterprise value is 278.72 billion.

Market Cap	258.06B
Enterprise Value	278.72B

Important Dates

The next confirmed earnings date is Wednesday, April 29, 2026.

Earnings Date	Apr 29, 2026
Ex-Dividend Date	Feb 19, 2026

Share Statistics

Current Share Class	1.55B
Shares Outstanding	n/a
Shares Change (YoY)	-0.06%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	0.04%
Owned by Institutions (%)	66.91%
Float	1.54B

Valuation Ratios

The trailing PE ratio is 29.63 and the forward PE ratio is 18.45.

PE Ratio	29.63
Forward PE	18.45
PS Ratio	5.16
PB Ratio	6.22
P/TBV Ratio	n/a
P/FCF Ratio	25.75
P/OCF Ratio	20.79
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.48, with an EV/FCF ratio of 27.82.

EV / Earnings	32.01
EV / Sales	5.52
EV / EBITDA	16.48
EV / EBIT	22.70
EV / FCF	27.82

Financial Position

The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.

Current Ratio	0.94
Quick Ratio	0.65
Debt / Equity	0.61
Debt / EBITDA	1.51
Debt / FCF	2.52
Interest Coverage	10.47

Financial Efficiency

Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.48%.

Return on Equity (ROE)	22.84%
Return on Assets (ROA)	8.19%
Return on Invested Capital (ROIC)	16.48%
Return on Capital Employed (ROCE)	17.12%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	520,583
Profits Per Employee	90,621
Employee Count	96,100
Asset Turnover	0.54
Inventory Turnover	1.81

Taxes

In the past 12 months, AstraZeneca has paid 1.85 billion in taxes.

Income Tax	1.85B
Effective Tax Rate	17.49%

Stock Price Statistics

The stock price has increased by +21.44% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+21.44%
50-Day Moving Average	165.20
200-Day Moving Average	144.60
Relative Strength Index (RSI)	46.24
Average Volume (20 Days)	1,039

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of EUR 50.03 billion and earned 8.71 billion in profits. Earnings per share was 5.57.

Revenue	50.03B
Gross Profit	40.88B
Operating Income	12.17B
Pretax Income	10.56B
Net Income	8.71B
EBITDA	16.42B
EBIT	12.17B
Earnings Per Share (EPS)	5.57

Balance Sheet

The company has 4.87 billion in cash and 25.30 billion in debt, with a net cash position of -20.43 billion.

Cash & Cash Equivalents	4.87B
Total Debt	25.30B
Net Cash	-20.43B
Net Cash Per Share	n/a
Equity (Book Value)	41.49B
Book Value Per Share	26.73
Working Capital	-1.61B

Cash Flow

In the last 12 months, operating cash flow was 12.41 billion and capital expenditures -2.39 billion, giving a free cash flow of 10.02 billion.

Operating Cash Flow	12.41B
Capital Expenditures	-2.39B
Free Cash Flow	10.02B
FCF Per Share	n/a

Margins

Gross margin is 81.71%, with operating and profit margins of 24.33% and 17.41%.

Gross Margin	81.71%
Operating Margin	24.33%
Pretax Margin	21.11%
Profit Margin	17.41%
EBITDA Margin	32.82%
EBIT Margin	24.33%
FCF Margin	20.03%

Dividends & Yields

This stock pays an annual dividend of 2.71, which amounts to a dividend yield of 1.63%.

Dividend Per Share	2.71
Dividend Yield	1.63%
Dividend Growth (YoY)	-7.66%
Years of Dividend Growth	4
Payout Ratio	47.39%
Buyback Yield	0.06%
Shareholder Yield	1.69%
Earnings Yield	3.37%
FCF Yield	3.88%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AstraZeneca has an Altman Z-Score of 3.24 and a Piotroski F-Score of 7.

Altman Z-Score	3.24
Piotroski F-Score	7